JV-394

Autologous anti-CD94 CAR T · MD Anderson Cancer Center

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JV-394, covering 2026-02-27 to 2026-02-27. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms [Phase 1]